Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cara Therapeutics stock in Canada | $13.22

Own Cara Therapeutics shares in just a few minutes.

Cara Therapeutics Inc
NASDAQ: CARA - USD
BIOTECHNOLOGY
$13.22
+ $0.52 ( + 4.09%)

Cara Therapeutics is a biotechnology business based in the US. Cara Therapeutics stocks (CARA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.66 – an increase of 3.04% over the previous week. Cara Therapeutics employs 80 staff and has a trailing 12-month revenue of around $123.3 million.

How to buy shares in Cara Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CARA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Cara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Cara Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Cara Therapeutics's stock price has had significant negative movement.

Its last market close was $13.22, which is 23.27% down on its pre-crash value of $17.23 and 48.87% up on the lowest point reached during the March crash when the stocks fell as low as $8.88.

If you had bought $1,000 worth of Cara Therapeutics stocks at the start of February 2020, those stocks would have been worth $678.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $810.52.

Cara Therapeutics stock price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$13.22
52-week range$11.22 - $29.65
50-day moving average $14.62
200-day moving average $15.43
Wall St. target price$25.63
PE ratio 74.7059
Dividend yield N/A (0%)
Earnings per share (TTM) $0.17

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
FREE TRADES
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get 2 free stocks when you open a Wealthsimple Trade personal account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
OFFER
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Cara Therapeutics price performance over time

Historical closes compared with the close of $13.22 from 2021-10-25

1 week (2021-10-19) 3.04%
1 month (2021-09-24) -17.01%
3 months (2021-07-26) 9.53%
6 months (2021-04-26) -50.13%
1 year (2020-10-26) -5.10%
2 years (2019-10-25) -34.10%
3 years (2018-10-26) 18.67
5 years (2016-10-26) 87.25%

Is Cara Therapeutics under- or over-valued?

Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cara Therapeutics's P/E ratio

Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 75x. In other words, Cara Therapeutics shares trade at around 75x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Cara Therapeutics's EBITDA

Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.1 million.

The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.

Cara Therapeutics financials

Revenue TTM $123.3 million
Operating margin TTM 5.54%
Gross profit TTM $27.2 million
Return on assets TTM 2.19%
Return on equity TTM 4.85%
Profit margin 6.78%
Book value $4.06
Market capitalisation $636.1 million

TTM: trailing 12 months

Shorting Cara Therapeutics shares

There are currently 2.1 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 30.2% down from 3.0 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 813307.27969349). Cara Therapeutics's SIR currently stands at 2.61. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 2610 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0432% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.

Cara Therapeutics share dividends

We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.

Have Cara Therapeutics's shares ever split?

Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.

Cara Therapeutics share price volatility

Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $11.22 up to $29.6473. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.1302. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cara Therapeutics overview

Cara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site